Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.33 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 3/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719889 | 1.00 | EPHX2 (0.36) | EPHX2EGLN1PIK3CDSPHK2SPHK1 | |
| SCHEMBL1720208 | 0.92 | SLC6A7 (0.37) | MAP3K7TAB1STAT3DGAT2 | |
| SCHEMBL1720205 | 0.92 | SLC6A7 (0.37) | MAP3K7TAB1STAT3DGAT2 | |
| SCHEMBL1719716 | 0.89 | EPHX2 (0.37) | EPHX2PIK3CDSPHK2SPHK1HTR2B | |
| SCHEMBL1719718 | 0.89 | EPHX2 (0.37) | EPHX2PIK3CDSPHK2SPHK1HTR2B | |
| SCHEMBL1719431 | 0.89 | EPHX2 (0.40) | EPHX2HTR2BCHRM3ABL1 | |
| SCHEMBL1719434 | 0.89 | EPHX2 (0.40) | EPHX2HTR2BCHRM3ABL1 | |
| SCHEMBL1724292 | 0.87 | MCHR1 (0.38) | EGLN1PIK3CDHTR2BSCN9ADGAT2 | |
| SCHEMBL1719995 | 0.86 | EPHX2 (0.40) | EPHX2PIK3CDHTR2BCHRM3MAP3K7 | |
| SCHEMBL1719996 | 0.86 | EPHX2 (0.40) | EPHX2PIK3CDHTR2BCHRM3MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173735-B1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-01-11 | — | — | EP | disclosed |
| US-7935707-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090012063-A1 | Novel imidazole derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012063-A1 | Novel imidazole derivatives | CCR2, CCR1, CCR3 | EPHX2 934/4885EGLN1 3168/4885PIK3CD 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.